Loading organizations...
China Grand Prosperity Investment (CGP) operates as a private equity asset management institution, pioneering Funds of Funds (FOFs) in China. Leveraging national resources and asset management expertise, the firm employs diversified investment models including FOFs, secondary funds, direct investments, and M&A. CGP focuses on developing effective management and exit strategies for the Chinese market.
Established in Beijing in 2010, the firm strategically positioned itself within China's evolving FOF market. Its inception addressed the increasing demand for specialized private equity investment vehicles. While founder details are not publicly disclosed, its early success indicates clear market insight.
CGP invests in strategic emerging industries like semiconductors, information technology, healthcare, and advanced manufacturing, covering all stages from angel to M&A. The firm’s mission is to promote industrial transformation and empower economic development through innovation. Adhering to an ESG investment philosophy, CGP strives for sustainable long-term value.
China Grand Prosperity Investment has 2 tracked investments across 1 company. The latest tracked deal is $44.1M Series C in LYNK Pharmaceuticals in September 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 21, 2023 | LYNK Pharmaceuticals | $44.1M Series C | China Grand Prosperity Investment | Lilly Asia Ventures, NEW Alliance Capital |
| Jun 1, 2023 | LYNK Pharmaceuticals | $28.1M Series C | — | Liando Investment |